Clinical Trial Search

Primary: Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal Rate — 48; 28…

Primary: Skin Swab and Culture With Colony Forming Units (CFUs) — 39; 51; 35; 22 negative skin cultures — p=0.68

Primary: Number of Subjects With Positive Bacterial Growth Culture Per Treatment Arms — 10; 12; 10; 10 participants

Primary: Relative Staphylococcus Aureus Abundance — 0.13; 12.2 ratio to baseline S. aureus abundance

Primary: Clinical Outcome in Participants With Baseline Methicillin-Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for Per-Protocol (PP) Population — 84.1; 79.9…

Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…

Primary: Shift From Baseline in Distortion Product Otoacoustic Emission at TOC Visit — 2; 1; 0; 0 Participants

Primary: Early Clinical Response — 306; 303 Participants

Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants

Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…

Primary: Number of Participants With PGA of 0 or 1 — 22; 14 participants — p=0.035

Primary: Impetigo Prevalence at 12 Months — 79; 66; 20; 12 Cases of impetigo

Primary: Objective Response of ≥20% Reduction in Lesion Erythema Area Compared to Baseline at 48 to 72 Hours After Initiation of Treatment as Determined by Digital Measurements…

Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants

Primary: Recurrence Rates of Abscesses — 4; 14 participants

Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant

Primary: Investigator's Assessment of Clinical Response in the ITT (Intent-to-treat) Population at Follow-up — 57; 50; 53 Participants

Primary: Number of Participants With Bacterial Growth Before and After Photodynamic Treatment and After Skin Antisepsis — 10; 10; 3; NA Participants

Primary: Number of Participants With a Clinical Response of Cure — 38; 34; 37 Participants

Primary: Early Clinical Efficacy — 285; 288; 86; 80 participants

Primary: Bacteriological Culture — 13; 3; 16; 5 participants

Primary: Number of Participants With Any Adverse Events (AE) and Serious Adverse Events (SAE) — 49; 20; 1; 1 Participants

Primary: Early Clinical Efficacy — 240; 233; 48; 52 participants

Primary: Number of Patients at the Early Assessment Visit With a 20% Reduction in ABSSSI Lesion Size Compared to Baseline — 72; 35 Participants

Primary: Clinical Response at Test of Cure (TOC) in the Clinically Evaluable (CE) Population — 33; 37; 31 Participants

Primary: Participants With Clinical Cure According to Investigator's Assessment — 167; 184; 174; 36 Participants

Primary: Number of Participants Whose Wound Cultures Were Positive for MRSA and Who Were Determined to be a Clinical Success at the Follow-up Visit — 5 participants

Primary: Re-infection With S. Aureus — 10; 11; 0; 0 participants with S. aureus re-infection — p=0.356

Primary: Number of Participants With Abscess Resolution — 11; 9 Participants

Primary: Number of Participants With a Clinical Cure — 45; 42 Participants — p=0.71